Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2024-02-27 00:00:00 ET · period of report 2024-02-23 · accession 0000875320-24-000097 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-02-27 | 2024-02-23 | VRTX | Ambrose Kristen | SVP, CAO | F - Tax | $431.79 | -828 | 8,848 | -9% | -$357.5K | |
| 2024-02-27 | 2024-02-26 | VRTX | Ambrose Kristen | SVP, CAO | S - Sale | $425.70 | -883 | 7,965 | -10% | -$375.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-23 | F | D | 828 | $431.79 | 8,848 | D | — | — | |
| 2 | Common | Common Stock | 2024-02-26 | S | D | 883 | $425.70 | 7,965 | D | — | — |